http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104013611-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2014-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104013611-B |
| titleOfInvention | Application of mango aglycone and derivative thereof in preparation of anti-prostate hyperplasia drug |
| abstract | The invention belongs to the field of medicines, and discloses novel application of a mango aglycone derivative. An in-vitro test shows that the mango aglycone derivative can obviously inhibit activity of 5 alpha-reductase, can remarkably lower prostate wet weight index of a testosterone propionate replication prostate hyperplasia model mouse, can lower a ratio of E2/T in blood serum, and can lower activity of the 5 alpha-reductase in a liver tissue, so that the mango aglycone derivative is indicated to have effect in inhibiting activity of 5 alpha-reductase, can be used for treating 5 alpha-reductase expression or superhigh-activity-associated diseases, for example testosterone propionate; moreover, the mouse stomach is filled with the drug in maximum administration dosage of 21.6g/kg, and therefore, the drug has very good clinical application prospect. |
| priorityDate | 2014-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 78.